CORPORATE FINANCIALS ONLINE Fastest direct links to news from publicly-traded companies.

                Competitive Tech: Confirms Patent Issuance



For Immediate Release  




          Competitive Technologies Confirms Issuance of Patent
   For Use of Alpha MSH Anologue in Stimulating Female Sexual Response

        Technology Exclusively Licensed to Palatin Technologies, Inc.


Fairfield, CT - (June 29, 2000) - Competitive Technologies, Inc. (AMEX:
CTT) confirmed today that the US Patent & Trademark Office has issued US
patent 6,051,555 containing claims for the use of various alpha MSH
peptide analogues for stimulating a sexual response in females.

Competitive Technologies has exclusively licensed the technology to
Palatin Technologies, Inc. (AMEX: PTN).  Revenues generating from any
FDA approved Palatin products using CTT technologies will produce
royalties for CTT and its client, the University of Arizona.

In an earlier release, Palatin announced that the US Food and Drug
Administration has approved the design of initial clinical trials for
PT-141, a male erectile dysfunction treatment using nasal spray to
stimulate receptors in the central nervous system.  PT-141 is a
synthetic modification of PT-14, an analogue of a naturally occurring
peptide hormone called Alpha MSH.

Palatin Technologies is a development-stage medical technology company
developing and commercializing pharmaceutical products for diagnostic
imaging and therapy based on its proprietary monoclonal antibody
radiolabeling and enabling peptide platform technologies.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in identifying, developing
and commercializing innovative life sciences, physical sciences and
digital technologies.  Competitive Technologies' specialized expertise
and experience make it a valuable partner for inventors, companies and
universities of all sizes.  CTT has been responsible for closing
hundreds of licensing agreements. CTT clients include:  Lucent
Technologies, Matsushita Electric Industrial, NTRU Cryptosystems,
Palatin Technologies, Inc. and Ribozyme Pharmaceuticals, Inc.
Competitive Technologies, Inc. is based in Fairfield, Connecticut and
has affiliates in Osaka, Japan and London, England.


Statements about the Company's future expectations, including
development and regulatory plans, and all other statements in this
document other than historical facts are "forward-looking statements"
within the meaning of applicable Federal Securities Laws and are not
guarantees of future performance.  These statements involve risks and
uncertainties related to market acceptance of and competition for the
Company's licensed technologies and other risks and uncertainties
inherent in CTT's business, including those set forth in Item 1 of the
Company's Form 10-K for the year ended July 31, 1999 and other factors
that may be described in CTT's filings with the SEC, and are subject to
change at any time. The Company's actual results could differ materially
from these forward-looking statements. The Company undertakes no
obligation to update publicly any forward-looking statement.


Direct inquiries to:

Johnnie D. Johnson
Strategic IR, Inc.
800 Third Avenue 
Suite 3700
New York, NY  10022
Tel. (212) 754-6565
Fax (212) 754-4333
E-mail: jdjohnson@strategic-ir.com

E-mail: ctt@competitivetech.net
Web site: http://www.competitivetech.net


End